HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
Leader of Global
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Immunomic Therapeutics, EPIVAX, Pha...
- Agreement of COVID-19 Vaccine Joint DevelopmentAccording to a foreign press reported at 5 o'clock in the morning, thre...
Elevar to accept Dr. Gelder for glo...
HLB and Elevar Therapeutics (Elevar) announced on the 26th that they have signed Mark Gelder, M.D. as Vice President o...
HLB Chairman Jin Yang-gon reveals h...
2020, the year HLB's grand goal began.Chairman Yang-Gon Jin of HLB announced HLB's strategy to become a global pharma....
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...